ORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co.
What You May Do
If you purchased securities of Organon and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-ogn/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by July 22, 2025.
About the Lawsuits
Organon and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 10, 2025, pre-market, the Company announced its financial results for the first quarter of 2025, disclosing, among other things, that management had reset the Company's dividend payout, from $0.28 to $0.02, contradicting its prior statements assuring investors that the regular quarterly dividend was a number one priority and that the Company was committed to its capital allocation strategy through the aforementioned dividend. On this news, the price of Organon's shares fell more than 27%, from a closing market price of $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025.
The first-filed case is Hauser v. Organon & Co., et al., No. 25-cv-05322. A subsequent case, Lerner v. Organon & Co., et al., No. 25-cv-12983, expanded the class period.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Newmont Corporation's (NYSE:NEM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Most readers would already know that Newmont's (NYSE:NEM) stock increased by 5.6% over the past three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to investigate if the company's decent financials had a hand to play in the recent price move. In this article, we decided to focus on Newmont's ROE. Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. How To Calculate Return On Equity? The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Newmont is: 16% = US$5.0b ÷ US$31b (Based on the trailing twelve months to March 2025). The 'return' is the yearly profit. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.16 in profit. See our latest analysis for Newmont Why Is ROE Important For Earnings Growth? Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. Newmont's Earnings Growth And 16% ROE To begin with, Newmont seems to have a respectable ROE. Further, the company's ROE compares quite favorably to the industry average of 12%. For this reason, Newmont's five year net income decline of 34% raises the question as to why the high ROE didn't translate into earnings growth. Based on this, we feel that there might be other reasons which haven't been discussed so far in this article that could be hampering the company's growth. Such as, the company pays out a huge portion of its earnings as dividends, or is faced with competitive pressures. So, as a next step, we compared Newmont's performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 11% over the last few years. Earnings growth is a huge factor in stock valuation. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. Has the market priced in the future outlook for NEM? You can find out in our latest intrinsic value infographic research report. Is Newmont Efficiently Re-investing Its Profits? Newmont's low LTM (or last twelve month) payout ratio of 23% (or a retention ratio of 77%) over the last three years should mean that the company is retaining most of its earnings to fuel its growth but the company's earnings have actually shrunk. The low payout should mean that the company is retaining most of its earnings and consequently, should see some growth. So there could be some other explanations in that regard. For example, the company's business may be deteriorating. Additionally, Newmont has paid dividends over a period of at least ten years, which means that the company's management is determined to pay dividends even if it means little to no earnings growth. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 20%. Accordingly, forecasts suggest that Newmont's future ROE will be 14% which is again, similar to the current ROE. Summary Overall, we feel that Newmont certainly does have some positive factors to consider. Although, we are disappointed to see a lack of growth in earnings even in spite of a high ROE and and a high reinvestment rate. We believe that there might be some outside factors that could be having a negative impact on the business. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
an hour ago
- Hamilton Spectator
Treatment.com AI Engages Marketing Services Providers
VANCOUVER, British Columbia, July 18, 2025 (GLOBE NEWSWIRE) — AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is pleased to announce that it has engaged 45 Degrees, Inc. ('45 Degrees') and Investment Publishing LLC ('Investment Publishing') to provide digital marketing and investor awareness services on behalf of Treatment as further described below. 45 Degrees: 45 Degrees of Cheyenne, WY, has been engaged by Treatment for a six-month term commencing immediately to provide advertising services including Google Ads, social media and video interview distribution (the 'Marketing Engagement'). The Marketing Engagement was entered into on July 18, 2025, in consideration of a total fee of USD $180,000 to be paid in two equal installments: USD $90,000 on signing and USD $90,000 due 10 weeks after the marketing campaign launch. The Marketing Engagement may be extended on a month-to-month basis for a fee of USD $25,000 by way of mutual written agreement between both parties. Furthermore, Treatment may elect to increase the scope of the services provided under the Marketing Engagement for accelerated reach, expanded content, or live media in consideration for an additional USD $10,000 per month. In connection with and as partial consideration for the Marketing Engagement, Treatment has issued400,000 stock options (each an 'Option') to the principal of 45 Degrees, which shall each be exercisable at $0.45 per common share of the Company. Such options shall vest immediately and shall be exercisable for a period of 3 years from the date of grant. The contact information for 45 Degrees is: 45 Degrees Inc, whose registered address is: 1621 Central Ave, Cheyenne WY 8200, USA. Email: info@ and phone; 672.906.2276. Investment Publishing: The Company has also engaged Investment Publishing pursuant to a marketing agreement dated July 18, 2025 to enhance the Company's investor relations strategy. The engagement of Investment Publishing is for an initial one year term commencing immediately and is designed to increase awareness of the Company. Investment Publishing will aim to engage investors through public relations efforts, educational content, and direct outreach using a range of digital platforms, including social media channels, email newsletters, and investor-focused webinars. As compensation for services to be provided, the Company will pay Investment Publishing, the Company will issue Investment Publishing's principal, Mariusz Skonieczny, 400,000 Options, which are each exercisable to acquire one common share of the Company at an exercise price of $0.45 for a period of three years from the date of grant. The Company looks forward to a productive collaboration with Investment Publishing as the Company continues to expand its reach and deliver value to stakeholders. Contact Information for Investment Publishing LLC: Name: Mariusz Skonieczny Email: marios188@ Business Address: 1202 Far Pond Cir. Mishawaka IN 46544. Option Grants The Company also announces that it has granted an aggregate of an additional 400,000 Options to certain arm's length consultants to the Company pursuant to the Company's stock option plan. Such Options, which vest immediately, are exercisable at an exercise price of $0.45 per common share of the Company for a period of 3 years from the date of grant. About AI Inc. AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, AI has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about AI's products and services: or email: info@ FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO ehamza@ For media inquiries, contact: media@ Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statements This news release contains forward-looking statements that are based on Treatment's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. These forward-looking statements or information may relate to the engagement of 45 Degrees and Investment Publishing and the anticipated benefits to Treatment from such engagement. Although Treatment believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Yahoo
an hour ago
- Yahoo
All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year
Key Points Income-focused investors seeking reliable dividends and a stable company can consider investing in telecommunications giant Verizon. AT&T's disciplined financial management is supporting its solid 4.1% dividend yield. AbbVie's ability to thrive post-Humira, combined with a 53-year history of dividend growth, makes it a smart buy now. 10 stocks we like better than Verizon Communications › It has been a volatile year for the U.S. markets, with many stocks experiencing impressive highs and sharp lows. Investing in such a turbulent environment may feel daunting for retail investors. However, dividend-paying stocks can help generate substantial passive income even amid market fluctuations. With the correct picks, investors can generate a steady dividend income even with a relatively modest investment. For instance, investing $2,000 each in Verizon Communications (NYSE: VZ), AT&T (NYSE: T), and AbbVie (NYSE: ABBV) will generate a total of $282.60 in passive income annually. Here's how the dividend income breaks down: With a 6.5% yield, $2,000 invested in Verizon will generate $130.20 in annual dividends. With a 4.1% yield, $2,000 invested in AT&T will generate $82.40 in annual dividends. With a 3.5% yield, $2,000 invested in AbbVie will generate $70 in annual dividends. These stocks are not only reliable dividend payers, but also boast strong business models and a rich and durable history of returning value to shareholders. Verizon Communications giant Verizon offers investors a sustainable 6.5% dividend yield, which translates to $2.71 annually per share, all backed by solid business fundamentals. It has raised its dividend for 18 consecutive years. Verizon's strong financial results underline the stability of its dividend policy. The company delivered its highest-ever quarterly adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $12.6 billion in the first quarter of fiscal 2025 (ending March 31). Free cash flow was $3.6 billion. With a dividend payout ratio of 64.2%, there are enough earnings to cover the dividend. The company's convergence strategy, which integrates its wireless and wireline networks (including 5G and fiber-optic networks) to create comprehensive connectivity solutions, has proven successful. This has helped reduce customer churn by 40% to 50% for both mobility and fiber products. A sticky customer base translates into predictable cash flows. Besides retaining existing customers, the company is also rapidly acquiring new clients. Verizon added 339,000 broadband customers and 308,000 fixed wireless customers in the first quarter. The company aims to achieve a goal of 100 million premises with fiber and fixed wireless access following the completion of its pending Frontier acquisition. Besides telecommunication services, Verizon built a robust adjacent services business (including discounted streaming services and other subscriptions, insurance products, and financial services) expected to clock an annual run rate of $2 billion by the end of 2025. The business also boasts mid-30s margins. Management is guiding for 2% to 3.5% adjusted EBITDA growth and free cash flows of $17.5 billion to $18.5 billion in 2025. This provides the required cushion for dividend sustainability. Hence, for investors seeking to earn passive income from high-quality companies, Verizon appears to be a smart buy now. AT&T Telecommunications giant AT&T is offering a solid 4.1% yield, which translates to $1.11 per share annually. The dividend also appears well-covered with a 68.1% dividend payout ratio, implying that the company also has the flexibility to increase dividends in the coming years. AT&T expects to resume share buybacks in the second quarter of fiscal 2025 as part of a $10 billion repurchase program, with at least $3 billion completed by the end of fiscal 2025, and the remainder allocated for fiscal 2026. AT&T has also been increasingly focusing on financial discipline. Since 2020, the company reduced its net debt by $32 billion. It ended the first quarter of fiscal 2025 with a net debt-to-adjusted EBITDA ratio of 2.63, lower than the 2.68 ratio at the end of fiscal 2024. In Q1, the company's revenues increased 2% to $30.6 billion, net income rose 23.6% year over year to $4.7 billion, and free cash flow increased 10.7% year over year to $3.1 billion. These numbers demonstrate AT&T's ability to fund its dividend policy sustainably while maintaining sufficient financial flexibility to invest in growth initiatives and repurchase shares. AT&T also has exceptional fiber and wireless businesses, both of which are relatively recession-resistant. The company is currently operating the largest fiber network in the U.S. and expects to hit 30 million fiber locations by mid-2025 and 50 million by 2029. This expansion is already driving strong customer growth, with 261,000 fiber net additions in Q1 alone. Additionally, the company's wireless network modernization and fixed wireless expansion contributed to a customer count increase of 181,000 during Q1. AT&T is also benefiting by bundling its services, creating stickier and more profitable customer relationships. AT&T Fiber and wireless services have 15% higher lifetime values than stand-alone customers. For income investors seeking defensive dividend growth, this transformed telecommunications player is an appealing pick now. AbbVie AbbVie also offers an impressive yield of 3.52% with an annual payout of $6.56 per share. With its history of increasing dividends for 53 consecutive years (including its Abbott Laboratories heritage), AbbVie sports the prestigious Dividend King status. When AbbVie lost the patent protection for its blockbuster immunology drug Humira in 2023, many investors were concerned about the sustainability of its dividend policy. However, the company has successfully reduced its over-reliance on Humira and continues to thrive even after the dreaded patent cliff. Humira's sales have fallen more than expected, decreasing by 49.5% year over year to $1.1 billion in Q1 of fiscal 2025. However, its next-generation immunology drugs Skyrizi and Rinvoq are showing impressive results, generating a combined $5.1 billion, a substantial 65% year-over-year increase. Management now expects these two drugs to generate $31 billion in combined sales by 2027, surpassing Humira's peak sales of $20.7 billion. In addition to immunology, AbbVie has successfully diversified into areas such as neuroscience, oncology, and aesthetics. The company is also focusing on strategic investments, including a $350 million obesity partnership with Gubra and plans for a $2.1 billion acquisition of CAR-T therapy developer Capstan Therapeutics. These deals will position AbbVie in several high-growth areas. Recently, however, AbbVie announced that the acquired in-process research and development (IPR&D) and milestone expenses have negatively affected its second-quarter earnings guidance. While these represent a short-term challenge, the deals can prove to be major growth drivers in the long run. With AbbVie proving its capability to navigate major patent cliffs while growing its dividend, I think the stock is worth considering in 2025. Should you invest $1,000 in Verizon Communications right now? Before you buy stock in Verizon Communications, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verizon Communications wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Manali Pradhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool recommends Verizon Communications. The Motley Fool has a disclosure policy. All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year was originally published by The Motley Fool
